Search Results - "Onuoha, Shimobi"

AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies by Meyer, Steffen, Woodward, Martin, Hertel, Christina, Vlaicu, Philip, Haque, Yasmin, Kärner, Jaanika, Macagno, Annalisa, Onuoha, Shimobi C., Fishman, Dmytro, Peterson, Hedi, Metsküla, Kaja, Uibo, Raivo, Jäntti, Kirsi, Hokynar, Kati, Wolff, Anette S.B., Meloni, Antonella, Kluger, Nicolas, Husebye, Eystein S., Podkrajsek, Katarina Trebusak, Battelino, Tadej, Bratanic, Nina, Peet, Aleksandr, Krohn, Kai, Ranki, Annamari, Peterson, Pärt, Kisand, Kai, Hayday, Adrian

“…APS1/APECED patients are defined by defects in the autoimmune regulator (AIRE) that mediates central T cell tolerance to many self-antigens. AIRE deficiency…”
Get full text

Trojan horses and guided missiles: targeted therapies in the war on arthritis by Ferrari, Mathieu, Onuoha, Shimobi C., Pitzalis, Costantino

“…Key Points Systemic drug administration often results in off-site, on-target activity as well as amplification of off-target effects, with increased risk of…”
Get full text

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies by Maciocia, Paul M, Wawrzyniecka, Patrycja A, Philip, Brian, Ricciardelli, Ida, Akarca, Ayse U, Onuoha, Shimobi C, Legut, Mateusz, Cole, David K, Sewell, Andrew K, Gritti, Giuseppe, Somja, Joan, Piris, Miguel A, Peggs, Karl S, Linch, David C, Marafioti, Teresa, Pule, Martin A

“…Pule and colleagues identify the TCR β-chain constant region as a new target for chimeric antigen receptor (CAR) T cells in treatment of T cell cancers while…”
Get full text

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial by Cordoba, Shaun, Onuoha, Shimobi, Thomas, Simon, Pignataro, Daniela Soriano, Hough, Rachael, Ghorashian, Sara, Vora, Ajay, Bonney, Denise, Veys, Paul, Rao, Kanchan, Lucchini, Giovanna, Chiesa, Robert, Chu, Jan, Clark, Liz, Fung, Mei Mei, Smith, Koval, Peticone, Carlotta, Al-Hajj, Muhammad, Baldan, Vania, Ferrari, Mathieu, Srivastava, Saket, Jha, Ram, Arce Vargas, Frederick, Duffy, Kevin, Day, William, Virgo, Paul, Wheeler, Lucy, Hancock, Jeremy, Farzaneh, Farzin, Domning, Sabine, Zhang, Yiyun, Khokhar, Nushmia Z., Peddareddigari, Vijay G. R., Wynn, Robert, Pule, Martin, Amrolia, Persis J.

“…Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause…”
Get full text

Going with the flow: harnessing the power of the vasculature for targeted therapy in rheumatoid arthritis by Ferrari, Mathieu, Onuoha, Shimobi C., Pitzalis, Costantino

“…Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disease that leads to excessive joint inflammation and is associated with significant morbidity…”
Get full text

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants by Ferrari, Mathieu, Mekkaoui, Leila, Ilca, F Tudor, Akbar, Zulaikha, Bughda, Reyisa, Lamb, Katarina, Ward, Katarzyna, Parekh, Farhaan, Karattil, Rajeev, Allen, Christopher, Wu, Philip, Baldan, Vania, Mattiuzzo, Giada, Bentley, Emma M, Takeuchi, Yasuhiro, Sillibourne, James, Datta, Preeta, Kinna, Alexander, Pule, Martin, Onuoha, Shimobi C

“…The human angiotensin-converting enzyme 2 acts as the host cell receptor for SARS-CoV-2 and the other members of the family SARS-CoV-1 and HCoV-NL63. Here, we…”
Get full text

Tunable control of CAR T cell activity through tetracycline mediated disruption of protein–protein interaction by Hotblack, Alastair, Kokalaki, Evangelia K., Palton, Morgan J., Cheung, Gordon Weng-Kit, Williams, Iwan P., Manzoor, Somayya, Grothier, Thomas I., Piapi, Alice, Fiaccadori, Valeria, Wawrzyniecka, Patrycja, Roddy, Harriet A., Agliardi, Giulia, Roddie, Claire, Onuoha, Shimobi, Thomas, Simon, Cordoba, Shaun, Pule, Martin

“…Chimeric antigen receptor (CAR) T cells are a promising form of cancer immunotherapy, although they are often associated with severe toxicities. Here, we…”
Get full text

Rational Design of Antirheumatic Prodrugs Specific for Sites of Inflammation by Onuoha, Shimobi C., Ferrari, Mathieu, Sblattero, Daniele, Pitzalis, Costantino

“…Objective Biologic drugs, such as the anti–tumor necrosis factor (anti‐TNF) antibody adalimumab, have represented a breakthrough in the treatment of rheumatoid…”
Get full text

Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis by Ferrari, Mathieu, Onuoha, Shimobi C, Fossati-Jimack, Liliane, Nerviani, Alessandra, Alves, Pedro L, Pagani, Sara, Deantonio, Cecilia, Colombo, Federico, Santoro, Claudio, Sblattero, Daniele, Pitzalis, Costantino

“…Biologic drugs, especially anti-TNF, are considered as the gold standard therapy in rheumatoid arthritis. However, non-uniform efficacy, incidence of…”
Get full text

Combining phage display with SMRTbell next-generation sequencing for the rapid discovery of functional scFv fragments by Nannini, Francesco, Senicar, Lenart, Parekh, Farhaan, Kong, Khai J, Kinna, Alexander, Bughda, Reyisa, Sillibourne, James, Hu, Xihao, Ma, Biao, Bai, Yuchen, Ferrari, Mathieu, Pule, Martin A, Onuoha, Shimobi C

“…Phage display technology in combination with next-generation sequencing (NGS) currently is a state-of-the-art method for the enrichment and isolation of…”
Get full text

Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies by Ferrari, Mathieu, Righi, Matteo, Baldan, Vania, Wawrzyniecka, Patrycja, Bulek, Anna, Kinna, Alexander, Ma, Biao, Bughda, Reyisa, Akbar, Zulaikha, Srivastava, Saket, Gannon, Isaac, Robson, Mathew, Sillibourne, James, Jha, Ram, El-Kholy, Mohamed, Amin, Oliver Muhammad, Kokalaki, Evangelia, Banani, Mohammed Amin, Hussain, Rehan, Day, William, Lim, Wen Chean, Ghongane, Priyanka, Hopkins, Jade R., Jungherz, Dennis, Herling, Marco, Welin, Martin, Surade, Sachin, Dyson, Michael, McCafferty, John, Logan, Derek, Cordoba, Shaun, Thomas, Simon, Sewell, Andrew, Maciocia, Paul, Onuoha, Shimobi, Pule, Martin

“…Peripheral T cell lymphomas are typically aggressive with a poor prognosis. Unlike other hematologic malignancies, the lack of target antigens to discriminate…”
Get full text

A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats by Nannini, Francesco, Parekh, Farhaan, Wawrzyniecka, Patrycja, Mekkaoui, Leila, Righi, Matteo, Dastjerdi, Fatemeh V., Yeung, Jenny, Roddie, Claire, Bai, Yuchen, Ma, Biao, Ferrari, Mathieu, Onuoha, Shimobi, Chester, Kerry, Pule, Martin

“…Antibody phage display is a powerful platform for discovery of clinically applicable high affinity monoclonal antibodies against a broad range of targets…”
Get full text

Knotted Fusion Proteins Reveal Unexpected Possibilities in Protein Folding by Mallam, Anna L., Onuoha, Shimobi C., Grossmann, J. Günter, Jackson, Sophie E.

“…Proteins that contain a distinct knot in their native structure are impressive examples of biological self-organization. Although this topological complexity…”
Get full text

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy by Lee, Lydia, Lim, Wen Chean, Galas-Filipowicz, Daria, Fung, Kent, Taylor, Julia, Patel, Dominic, Akbar, Zulaikha, Alvarez Mediavilla, Elena, Wawrzyniecka, Patrycja, Shome, Debarati, Reijmers, Rogier M, Gregg, Trillian, Wood, Leigh, Day, William, Cerec, Virginie, Ferrari, Mathieu, Thomas, Simon, Cordoba, Shaun, Onuoha, Shimobi, Khokhar, Nushmia, Peddareddigari, Vijay, Al-Hajj, Muhammad, Cavet, Jim, Zweegman, Sonja, Rodriguez-Justo, Manuel, Yong, Kwee, Pule, Martin, Popat, Rakesh

“…BackgroundWe used a proliferating ligand (APRIL) to construct a ligand-based third generation chimeric antigen receptor (CAR) able to target two myeloma…”
Get full text

Optimised Method for the Production and Titration of Lentiviral Vectors Pseudotyped with the SARS-CoV-2 Spike by Mekkaoui, Leila, Bentley, Emma M, Ferrari, Mathieu, Lamb, Katarina, Ward, Katarzyna, Karattil, Rajeev, Akbar, Zulaikha, Bughda, Reyisa, Sillibourne, James, Onuoha, Shimobi, Mattiuzzo, Giada, Takeuchi, Yasuhiro, Pule, Martin

“…The use of recombinant lentivirus pseudotyped with the coronavirus Spike protein of SARS-CoV-2 would circumvent the requirement of biosafety-level 3 (BSL-3)…”
Get full text

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR by Ghorashian, Sara, Kramer, Anne Marijn, Onuoha, Shimobi, Wright, Gary, Bartram, Jack, Richardson, Rachel, Albon, Sarah J., Casanovas-Company, Joan, Castro, Fernanda, Popova, Bilyana, Villanueva, Krystle, Yeung, Jenny, Vetharoy, Winston, Guvenel, Aleks, Wawrzyniecka, Patrycja A., Mekkaoui, Leila, Cheung, Gordon Weng-Kit, Pinner, Danielle, Chu, Jan, Lucchini, Giovanna, Silva, Juliana, Ciocarlie, Oana, Lazareva, Arina, Inglott, Sarah, Gilmour, Kimberly C., Ahsan, Gulrukh, Ferrari, Mathieu, Manzoor, Somayya, Champion, Kim, Brooks, Tony, Lopes, Andre, Hackshaw, Allan, Farzaneh, Farzin, Chiesa, Robert, Rao, Kanchan, Bonney, Denise, Samarasinghe, Sujith, Goulden, Nicholas, Vora, Ajay, Veys, Paul, Hough, Rachael, Wynn, Robert, Pule, Martin A., Amrolia, Persis J.

“…Chimeric antigen receptor (CAR)-modified T cells targeting CD19 demonstrate unparalleled responses in relapsed/refractory acute lymphoblastic leukemia (ALL) 1…”
Get full text

An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma by Lee, Lydia, Draper, Benjamin, Chaplin, Neil, Philip, Brian, Chin, Melody, Galas-Filipowicz, Daria, Onuoha, Shimobi, Thomas, Simon, Baldan, Vania, Bughda, Reyisa, Maciocia, Paul, Kokalaki, Eva, Neves, Margarida P., Patel, Dominic, Rodriguez-Justo, Manuel, Francis, James, Yong, Kwee, Pule, Martin

“…B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM), but expression is variable, and early reports of BCMA targeting…”
Get full text

A Rapamycin-Activated Caspase 9-Based Suicide Gene by Stavrou, Maria, Philip, Brian, Traynor-White, Charlotte, Davis, Christopher G., Onuoha, Shimobi, Cordoba, Shaun, Thomas, Simon, Pule, Martin

“…Engineered T cell therapies show considerable promise in the treatment of refractory malignancies. Given the ability of engineered T cells to engraft and…”
Get full text

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR by Kokalaki, Evangelia, Ma, Biao, Ferrari, Mathieu, Grothier, Thomas, Hazelton, Warren, Manzoor, Somayya, Costu, Eren, Taylor, Julia, Bulek, Anna, Srivastava, Saket, Gannon, Isaac, Jha, Ram, Gealy, Rosalind, Stanczuk, Lukas, Rizou, Tatiana, Robson, Mathew, El-Kholy, Mohamed, Baldan, Vania, Righi, Matteo, Sillibourne, James, Thomas, Simon, Onuoha, Shimobi, Cordoba, Shaun, Pule, Martin

“…CAR T cells recognizing CD19 effectively treat relapsed and refractory B-ALL and DLBCL. However, CD19 loss is a frequent cause of relapse. Simultaneously…”
Get full text

Anti-CD21 Chimeric Antigen Receptor (CAR)-T Cells for T Cell Acute Lymphoblastic Leukaemia (T-ALL) by Maciocia, Nicola C, Burley, Amy, Nannini, Francesco, Wawrzyniecka, Patrycja, Neves, Margarida, Karpanasamy, Thaneswari, Ferrari, Mathieu, Marafioti, Teresa, Onuoha, Shimobi, Khwaja, Asim, Maciocia, Paul M, Pule, Martin

“…CAR-T cell therapy against CD19 has changed the treatment landscape in relapsed/refractory (r/r) B-ALL. R/r T-ALL has a dismal prognosis, with an unmet need…”
Get full text